Encompass Health Corporation $EHC Shares Sold by Wellington Management Group LLP

Key Points

• Wellington Management Group LLP reduced its stake in Encompass Health by 10.2%, selling 411,836 shares, and now owns approximately 3.59% of the company, valued at $366.49 million.
• Encompass Health reported $1.40 earnings per share (EPS) for the last quarter, exceeding analyst expectations, with a revenue of $1.46 billion, up 12% year-over-year.
• The company announced an increase in its quarterly dividend from $0.17 to $0.19 per share, reflecting a 0.6% yield based on the current payout ratio of 14.87%.

Wellington Management Group LLP decreased its holdings in shares of Encompass Health Corporation (NYSE:EHC - Free Report) by 10.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,618,606 shares of the company's stock after selling 411,836 shares during the period. Wellington Management Group LLP owned approximately 3.59% of Encompass Health worth $366,492,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in EHC. Cerity Partners LLC grew its stake in shares of Encompass Health by 76.9% in the 4th quarter. Cerity Partners LLC now owns 5,837 shares of the company's stock valued at $547,000 after purchasing an additional 2,537 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Encompass Health by 63.1% during the fourth quarter. Renaissance Technologies LLC now owns 50,900 shares of the company's stock worth $4,701,000 after purchasing an additional 19,700 shares during the period. Barclays PLC grew its position in Encompass Health by 89.0% in the 4th quarter. Barclays PLC now owns 115,045 shares of the company's stock valued at $10,624,000 after buying an additional 54,167 shares during the last quarter. Mariner LLC increased its stake in Encompass Health by 24.6% in the 4th quarter. Mariner LLC now owns 4,251 shares of the company's stock valued at $393,000 after buying an additional 838 shares during the period. Finally, NewEdge Advisors LLC raised its position in Encompass Health by 5.3% during the 4th quarter. NewEdge Advisors LLC now owns 8,209 shares of the company's stock worth $758,000 after buying an additional 412 shares during the last quarter. Institutional investors and hedge funds own 97.25% of the company's stock.

Encompass Health Trading Up 1.6%

Encompass Health stock opened at $122.1270 on Wednesday. The stock has a 50-day moving average price of $116.19 and a 200 day moving average price of $109.87. Encompass Health Corporation has a 52 week low of $87.85 and a 52 week high of $123.13. The stock has a market cap of $12.30 billion, a PE ratio of 23.90, a P/E/G ratio of 2.10 and a beta of 0.86. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.76.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.20. The company had revenue of $1.46 billion for the quarter, compared to analysts' expectations of $1.43 billion. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. The firm's revenue for the quarter was up 12.0% compared to the same quarter last year. During the same period last year, the company earned $1.11 EPS. Encompass Health has set its FY 2025 guidance at 5.120-5.340 EPS. Equities research analysts predict that Encompass Health Corporation will post 4.8 earnings per share for the current fiscal year.

Encompass Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Wednesday, October 1st will be issued a $0.19 dividend. This is a boost from Encompass Health's previous quarterly dividend of $0.17. The ex-dividend date is Wednesday, October 1st. This represents a $0.76 annualized dividend and a yield of 0.6%. Encompass Health's payout ratio is presently 14.87%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Royal Bank Of Canada lifted their target price on shares of Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a report on Monday, April 28th. Stephens upgraded shares of Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 price objective for the company in a research report on Thursday, June 5th. Truist Financial boosted their target price on Encompass Health from $135.00 to $140.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. Barclays raised their price target on Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Finally, Wall Street Zen downgraded Encompass Health from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. One analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $134.00.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.